
Opinion|Videos|December 5, 2024
Unmet Needs in the Management of Patients with Hyperlipidemia
Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP, discusses how maximally tolerated statin therapy often fails to achieve target low-density lipoprotein cholesterol levels in high-risk patients with atherosclerotic cardiovascular disease and share strategies for optimizing adherence, including when to switch therapies to improve patient outcomes.
Advertisement
Episodes in this series

Now Playing
Video content above is prompted by the following:
- In your clinical experience, how frequently does maximally tolerated statin therapy fail to lower low-density lipoprotein cholesterol levels below 70 mg/dL in high-risk patients with atherosclerotic cardiovascular disease?
- How about levels below 55 mg/dL?
- Patient adherence to statins is often suboptimal. What are your best methods to optimize adherence?
- In which scenarios do you switch patients’ therapies to optimize adherence?
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
State Pharmacy Boards Must Step Up Against Illegal Retatrutide
2
Obinutuzumab-Bendamustine Produces High Response Rates in Chinese Patients With Indolent B-Cell Lymphomas
3
New CKD Outcome Set Tells Pharmacists What to Measure
4
GLP-1s and the HCM–Sleep Apnea–Obesity Connection
5





































































































